Compare Recursion Pharmaceuticals Inc (RXRX) vs Ventas Inc. Common Stock (VTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Ventas Inc. Common Stock — how do they compare? Recursion Pharmaceuticals Inc trades at $4 (market cap $2.31B), while Ventas Inc. Common Stock trades at $80.12 (market cap $41.06B). The key difference: Ventas Inc. Common Stock is far larger — about 17.8× Recursion Pharmaceuticals Inc's market cap, and Ventas Inc. Common Stock pays a 2.6% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Ventas Inc. Common Stock for 0 Days on average.
| RXRX | VTR | |
|---|---|---|
Market Cap | $2.31B | $41.06B |
Volume | 40,478,768 | 4,174,820 |
Sector | Health | Real Estate |
52-Week High | $6.79 | $100.53 |
52-Week Low | $2.84 | $67.45 |
Typical Hold Time | 22 Days | 0 Days |
Enterprise Value | $1.83B | $53.78B |
Dividend Yield | — | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Ventas Inc. Common Stock
Ventas is a real estate investment trust focused on healthcare properties. Its portfolio includes senior housing, medical office buildings, and research-related facilities.
Read more on VTR →
